References
- Grossbard M. I., Press O. W., Applebaum F. R., Bernstein I. D., Nadler L. M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863–78
- Hale G., Xia M. Q., Tighe H. P., Dyer M. J. S., Waldmann H. The CAMPATH antigen (CDw52). Tissue Antigens 1990; 35: 1–10
- Carroll A. R., Rowlands D. J., Clarke B. E. Synthesis and secretion of a functional antibody in a vaccinia virus expression system. Molecular Immunology 1992; 29: 821–7
- Crowe J. S., Hall V. S., Smith M. A., Cooper H. J., Title J. P. Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanism of myeloma and Chinese hamster ovary cell-derived material. Clin. and Exp. Immun. 1992; 87: 105–10
- Willemze R., Richel D. J., Falkenburg J. H., Hale G., Waldmann H., Zwaan F. E., Fibbe W. E. In vivo use of CAMPATH-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. Bone Marrow Transplantation 1992; 9: 255–61
- Dreger P., Muller-Rucholtz W. Evidence that reduction of immunogenicity of T-depleted bone marrow depends on additional depletion of accessory cells. Transplan. 1990; 49: 622–30
- Cobbold S. P., Hale G., Clark M. R., Waldmann H. Purging auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms. Progress in Clinical & Biological Research 1990; 333: 139–51
- Kyle V., Roddy J., Hale G., Hazleman B. L., Waldmann H. Humanized monoclonal antibody treatment in rhuematoid arthritis. Journal of Rheumatology 1991; 18: 1737–8
- Watts R. A., Isaacs J. D., Hale, G B. L. H., Waldmann H. CAMPATH-1H in inflammatory arthritis. Clin. & Exper. Rheum. 1993; 11: S165–7, Suppl 8
- Lim S. H., Hale G., Marcus R. E., Waldmann H., Baglin T. P. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. British Journal of Haematology 1993; 84: 542–4
- Isaacs J. D., Watts R. A., Hazleman B. L., Hale G., Keogan M. T., Cobbold S. P., Waldmann H. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748–52
- Janson D., Nissel-Horowitz S., Sattler M., Rai K. R. Complete and Partial Response (CR, PR) in Treatment of Advanced Refractory b-cell Chronic Lymphocytic Leukemia (B-CLL) Using CAMPATH-1H. Blood: American Society of Hematology 1993; 82: 139a
- Barge R. M. Y., Dyer M. J. S., Matutes E., Kluin-Nelemans J. C., Fussell J. C., Niemer D., Fibbe W. E., Nethersell A. B. W., Catovsky D., Willemze R. Successful remission-induction of T-cell prolymphocytic leukemia (T-PLL) with humanized MoAb CAMPATH-1H (CP-1H). Blood: American Society of Hematology 1993; 82: 139a
- Hale G., Clark M. R., Marcus R. Remission Induction in non-Hodgkin's Lymphoma with Reshaped Human Monoclonal antibody CAMPATH-1H. Lancet 1988; II: 1394–9
- Dyer M. S., Hale G., Marcus R., Waldmann H. Remission Induction in Patients with Lymphoid Malignancies Using Unncojugated CAMPATH-1H Monoclonal Antibodies. Leukemia and Lymphoma 1990; 2: 179–93
- Dyer M. J. S., Hale G., Hayhoe F. G. J., Waldman H. Effects of CAMPATH-1H antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 1989; 73: 1431–1434
- Rai K. R., Hoffman M., Janson D., Fuchs A., Sheude N., Kollipora R., Sawitsky A. Immunosuppression and opportunistic infections in patients with chronic lymphocytic leukemia following CAMPATH-1H therapy. Blood 1995; 86: 348a, suppl.)
- Maloney D. G., Liles T. M., Czerwinski D. K. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDECC2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457–2466